WO1998047562A1 - Electrodes and electrode arrays - Google Patents
Electrodes and electrode arrays Download PDFInfo
- Publication number
- WO1998047562A1 WO1998047562A1 PCT/US1998/008183 US9808183W WO9847562A1 WO 1998047562 A1 WO1998047562 A1 WO 1998047562A1 US 9808183 W US9808183 W US 9808183W WO 9847562 A1 WO9847562 A1 WO 9847562A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- electrodes
- electrode
- electrical
- recited
- triangle
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0412—Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
- A61N1/0416—Anode and cathode
- A61N1/0424—Shape of the electrode
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0432—Anode and cathode
- A61N1/044—Shape of the electrode
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0472—Structure-related aspects
- A61N1/0476—Array electrodes (including any electrode arrangement with more than one electrode for at least one of the polarities)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/326—Applying electric currents by contact electrodes alternating or intermittent currents for promoting growth of cells, e.g. bone cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
- A61N1/303—Constructional details
- A61N1/306—Arrangements where at least part of the apparatus is introduced into the body
Definitions
- the present invention relates to the delivery of electrical waveforms and, more particularly, to the design of electrodes and electrode arrays for efficiently delivering electrical waveforms in vivo.
- Iontophoresis involves the application of electric currents to drive or repel oppositely charged particles through tissue. Iontophoretic devices have been known since the early 1900's. U.S. Pat. Nos. 3,991,755; 4,141,359; 4,398,545 and 4,250,878 disclose examples and some applications of such devices.
- Electro-osmosis occurs when an electric field is applied parallel to a charged surface in contact with a solution. The net ion movement causes a hydrodynamic flow of all molecules which are nearby in the solution (Dimitrov et al. (1990)). During electroporation, the transport of therapeutic agent across the cell membrane is commonly believed to involve diffusion, the movement of molecules from areas of higher concentration to areas of lower concentration. This transmembrane movement into the cytosol of electroporated cells may be enhanced by electro-osmosis (Sowers
- Electroporation refers to the application of electric fields of sufficient intensity and duration as to induce transient increases in cell membrane permeability.
- the cell membrane is a selectively permeable barrier that greatly inhibits the penetration of many therapeutic agents into the cytosol.
- Mir et al. (1992) report a 10, 000-fold increase in the cytotoxic activity of bleomycin, a normally impermeable chemotherapeutic agent, in the electroporated cells.
- Rols et al. (1990) describe electroporation as a threshold dependent phenomenon in that electric field intensity must be higher than a critical threshold to induce cell permeability. They further report that the extent and duration of membrane permeabilization is dependent on pulse duration and number. Provided that the electric field strength was not too high and the pulse duration not too long, electroporation of the cell membrane appears reversible (Zimmerman (1986) pg 177). Thus there exists an opportunity for the use of electroporation of cell membranes to achieve therapeutic benefits. In order to achieve success, the electric fields propagated in tissue by the delivery of specific electrical waveforms must apply sufficient transmembrane voltage and pulse duration to induce cell membrane permeability, yet not exceed inherent upper limits leading to cell lysis (death).
- Nishi, et al. (1996), Ceberg, et al. (1994), Salford, et al. (1993) and Okino, et al. (1987) also describe two electrode systems for tissue electroporation. Where described therein, the electrodes are of rod type (needle) construction, acutely placed in tissue, and spaced approximately 0.5-2cm apart.
- the prior art does not provide clear guidance as to the need for uniformity in the electric field propagation. Additionally, there are not known to be methods for the confinement of threshold level field intensities to the targeted tissue.
- panel A the electric field propagated in tissue by a two electrode system 20a-20b as described in the prior art would be considerably weaker in the region of tissue that is proximal to the midpoint between the electrodes (represented as the dashed box 22).
- the field strength in the tissue will weaken geometrically as the distance from either electrode 20a, 20b is increased (panel B), and the field strength in the mid-region of tissue will also weaken geometrically as the distance "L" between the two electrodes is increased.
- electroporation is considered to be a threshold-dependent phenomenon, with inherent upper limits due to the risk of cell lysis, a two electrode system is poorly suited to establish uniform electric field coverage, i.e., uniform electroporation, in the tissue targeted for treatment.
- Plate-type electrodes 24a, 24b aligned in parallel have been proposed to provide a uniform electric field 26 for electrochemotherapy delivered transcutaneously (U.S. Pat. No. 5,468,223 to Mir), and U.S. Pat. No. 5,439,440 to
- Hofmann describes an electrode for in vivo electroporation as spaced apart parallel arrays of needle electrodes 28a, 28b, 28c, 28d mounted on a dielectric support member 30 (see Figure 3).
- This design allows adjustments in needle depth and spacing between the parallel arrays (separated by distance L), but not the spacing of electrodes within each array 32.
- the array design has features that suggest similarity to the plate-type electrodes of Figure 2.
- the spacing 32 between adjacent electrodes 28a, 28b in the same array would need to be in the range of 0.25 L or less.
- the anatomy of the tissue involved may limit the number of electrodes that can be spaced within the targeted region.
- the needle arrays are described as adjustable in depth, there is no disclosure providing a means to confine the field effects for deep tissue applications in the third dimensional axis relative to the electrode arrays.
- the present invention provides electrode and electrode array apparatus which facilitates the efficient delivery of electrical waveforms, and particularly delivery to a predetermined three dimensional region of tissue within a patient. Electrical waveforms of certain parameters, comprising many different therapeutic objectives and techniques, may be efficiently delivered through the present invention, while minimizing the risk of trauma to the patient.
- the invention provides an electrode array having at least three individually addressable electrodes disposed so as to form a triangle in a plane intersecting the electrodes.
- a system wherein the electrode array is located in situ in a patient. When combined with elongate electrodes having defined conductive regions, the system defines a predetermined treatment region within the tissue of the patient.
- a further aspect of the invention provides an elongate electrode apparatus having a means for connecting the electrode to a source of electrical signals, an electrically conductive region located distal to the connecting means, and an electrically nonconductive region located proximal to the connecting means.
- the invention also provides an efficient means of expanding the electrode array "cell,” or any alternative cell design, into a multi-cell grid for controlled electric field propagation in an expanded cross sectional area of the predetermined region.
- individual electrodes may be of varying lengths and proportions, comprising a distal electrically-conductive portion and a proximal electrically- nonconductive portion.
- panel A is a two dimensional schematic view depicting the field lines and approximate electric field intensity for a two electrode model, wherein the intra- electrode distance is L and the dashed box positioned midway between the two electrodes indicates the region of lowest electric field strength, and panel B is a graphic representation of the relationship between the distance from the electrode and the electric field strength;
- Figure 2 is a schematic view depicting the field lines and approximate electric field strength for a plate electrode model, wherein the plates generate approximately uniform fields in the central region and weaker fringe electric fields at the edges;
- Figure 3 depicts an electrode array of the prior art which includes spaced apart parallel arrays of needle electrodes mounted on a dielectric support member;
- Figure 4 depicts an electrode array configuration in accordance with the invention, exemplified as a tricell array mounted on a dielectric support member;
- Figure 5 depicts the electric field generated in the array of Figure 4 in a characteristic trilobe pattern, wherein the shaded area indicates the region where the electric field strength exceeds the electroporation threshold;
- Figure 6 depicts three interlocking trilobe field patterns resulting from the sequentially shifting electric field activation of the array of Figure 4;
- Figure 7 illustrates a box array of needle electrodes with a core electrode mounted on a dielectric support member;
- Figure 8 illustrates a box array of needle electrodes without a core electrode mounted on a dielectric support member
- Figure 9 depicts a hexagonal electrode array of needle electrodes mounted on a dielectric support member
- Figure 10 depicts the expansion of the tricell array of Figure 4 into a trigrid pattern of interlocking tricells
- Figure 11 depicts the use of a four channel control means to activate the tricells in a trigrid, so as to provide the interlocking trilobe field patterns of Figure 6;
- Figure 12 depicts the individual trilobe field patterns resulting from the four channel control means used to activate the tricells in a trigrid, with the arrows indicating the polarity along coincident lines;
- Figure 13 depicts the expansion of the box array of Figure 7 into a multi cell grid pattern of overlapping cells;
- Figure 14 depicts the expansion of the box array of Figure 8 into a multi cell grid pattern of overlapping cells
- Figure 15 depicts the expansion of the hexagonal array of Figure 9 into a multi cell grid pattern of overlapping cells
- Figure 16 depicts the placement of an electrode array of the invention in situ in the brain of a patient
- Figure 17 depicts cascaded electrical signal pulses of increasing electric field intensity
- Figure 18 depicts the cascaded pulses of Figure 17, followed by pulses creating electric fields of decreasing intensity
- Figure 19 is a Kaplan-Meier survival chart for the experimental subjects described in example 2;
- Figure 20 is a Kaplan-Meier survival chart for the experimental subjects described in example 3;
- Figure 21 is a Kaplan-Meier survival chart for the experimental subjects described in example 4.
- Figure 22 is a Kaplan-Meier survival chart for the experimental subjects described in example 5.
- the present invention provides apparatus and systems which facilitate the efficient delivery of electrical waveforms, and particularly such waveform delivery to a predetermined three dimensional region of tissue within a patient. Electrical waveforms of certain parameters, comprising many different therapeutic objectives and techniques, may be efficiently delivered through the present invention, while minimizing the risk of surgical trauma to the patient.
- the invention provides an electrode array having at least three individually addressable electrodes disposed so as to form a triangle in a plane intersecting the electrodes.
- the electrodes can be provided in any form capable of conducting an electrical signal and establishing an electric field between oppositely- charged electrodes. Desirably, such electrodes will be of surgical quality, bio- compatible, and capable of withstanding the demands of implantation and use in a patient. Materials commonly employed in the construction of such electrodes include nickel titanium, gold, silver, stainless steel, platinum, platinum iridium alloys, graphite, ceramic, and the like.
- the electrodes will be elongate, for example rod electrodes 34a, 34b, 34c (see Figure 4), so as to simplify the surgical implantation of the electrode in the patient.
- rod electrodes such as acupuncture needles, which are usually of surgical quality, strength and (presumptively) bio-compatible stainless steel construction.
- needles such as acupuncture needles, which are usually of surgical quality, strength and (presumptively) bio-compatible stainless steel construction.
- the relatively sharp point of such a needle electrode may provoke arcing of the electric field, particularly at the electrode delivering the electrons in the propagation of the electric field (i.e. the "pulse electrode").
- the point of the electrode distal from the source of electrical signals includes a radius of curvature sufficient to substantially eliminate arcing at the electric field strengths utilized in the practice of the present invention, for example in the range of 0.1 to 1mm. It has also been found that the diameter of the rod electrode has a similar effect on arcing potential, due in part to the relationship of the electrode diameter to the radius of curvature of the point.
- the rod electrode itself will desirably also be of sufficient diameter to satisfy the arcing-reduction conditions as well.
- Such elongate electrodes will desirably include a means for connecting to a source of electrical signals 36 and a non-conductive region 38 located proximal to the signal source.
- non-conductive is taken to mean that the electrode does not permit an electric field to propagate radially from the electrode in the non-conductive region, while allowing the electrical signal or waveform to proceed axially or longitudinally through the non-conductive region.
- Such electrodes will also include a conductive region 40 located distal from the signal source.
- these electrode regions 38, 40 can be provided by shielding portions of the electrode 34 with a dielectric material, for example, with plastic, Teflon ® , ceramic, graphite, polyimide, and the like.
- the electrode may be of composite construction, for example where the cross sectional diameter of the electrode is maintained relatively constant in order to facilitate insertion of the electrode 34 into the tissue of the patient.
- such an electrode 34 with a nonconductive region 38 will permit the establishment of a predetermined region of tissue for treatment, where two of the dimensions are established by the geometry of the electrode array, and the third dimension is established by the length of the conductive region 40 of the electrode 34, i.e. the "effective electrode length.”
- one aspect of the invention is a three electrode array (termed a "tricell") comprising three elongate electrodes of predetermined length, disposed approximately parallel to each other, and spatially oriented in the "X" and "Y" dimensions of a three dimensional predetermined region, desirably in the approximate geometrical shape of an equilateral triangle.
- the "Z" or third dimension of the predetermined region is dependent on the effective electrode length established by the conductive region(s).
- a system is provided wherein the present electrode array is located in situ in a patient. When combined with elongate electrodes having defined conductive regions establishing effective electrode lengths, the system defines a predetermined treatment region within the tissue of the patient.
- This predetermined treatment region can then be subject to the electropermeabilization effects of the electric fields, promoting the introduction of therapeutic agents into cells within the region.
- the present invention can be readily applied in any environment in which the delivery of electrical waveforms is considered desirable, the invention is particularly suited for the delivery of electrical waveforms in vivo to patients expected to benefit from such treatment.
- Such therapeutic uses presently include bone repair, dermal wound healing, nerve regeneration, transport and delivery of therapeutic agents, and the like.
- the invention will find use in aiding in the administration of therapeutic agents in situations in which such administration has been considered problematic. Among these situations are included chemotherapy, and particularly chemotherapeutic treatment of brain tumors.
- the term "therapeutic agent” includes pharmacological agents, chemotherapeutic agents, nucleic acids, genes, antibodies and all other compositions which provide therapeutic benefit to a patient in need of treatment.
- One therapeutic application of electroporation consists of infusion of an anti-cancer drug into the patient, and electroporation of the drug into the tumor cells by applying electric fields between the electrodes.
- the present invention provides an array of individual electrodes organized into a geometry which efficiently delivers electrical waveforms to a predetermined region of tissue within a patient.
- One aspect of this efficiency is to maximize the electrical waveform intensity and uniformity for a given intra-electrode distance while minimizing the actual number of electrodes which must be placed in order to insure complete coverage of the predetermined treatment region
- the present invention thus provides an apparatus comprising an electrode array of a pre-determined geometry which can be implanted as a system in situ in a patient.
- the electrodes are each connected through conductive cables to a high voltage switching device, for example a Cyto PulseTM PA- 101 sequencer (available from Cyto Pulse Sciences, Inc., Columbia, Maryland) with software modifications to permit simultaneous activation of multiple electrodes.
- the switching device will in turn be connected to a suitable power supply or pulse generator, for example, a Cyto PulseTM PA 2000 or PA 4000 power supply, or a BTXTM T820 power supply (available from Genetronics, San Diego, California).
- the switching of electrical signals between the individual electrodes can be accomplished by numerous means, e.g. manually, mechanically, electrically, or by means of a circuit controlled by a programmed digital computer.
- the precise mechanism used in switching the electrical signals between individual electrodes will largely be chosen as a matter of convenience.
- the amplitude of the waveform applied to the array is based on the intra-electrode distance and should be selected so as to propagate electric field strengths sufficient to obtain the intended therapeutic benefits.
- the present array will allow for the efficient delivery of the electrical waveforms to the predetermined tissue region within the patient.
- an array as described above is disposed within the tissue of a host patient so as to adequately define the intended region for therapeutic treatment. Once the array is established and connected to the pulse generator, electric signals are directed to the electrodes in order to propagate electric fields of predetermined amplitude and duration through the tissue between the electrodes.
- the parameters of the signal are generally selected so that the tissue between the electrodes is subjected to electric fields strengths of high intensity and short duration.
- the voltage will be adjusted so that the generated field has the desired intensity.
- These fields will make the membranes of preselected cells in the tissue transiently permeable in order to permit the therapeutic agents to enter the cells in the predetermined region. This transient increase in permeability is believed to result from the temporary formation of pores within the cell membranes large enough to permit migration of the agent through the membrane and into the cytosol.
- the present array can be desirably established as conductive rod electrodes 34a, 34b, 34c, optionally mounted on an insulated or dielectric carrier or support member 45 and held in a predetermined geometry while allowing the electrodes to be inserted to a desired depth in the tissue.
- the electrodes can be implanted individually, and then optionally affixed to a support or directly to the patient (as depicted schematically in Figure 16).
- the electrodes can be provided with a penetration stop so that the predetermined depth of insertion can be achieved in minimal time.
- the geometry of the array established on the carrier can be subject to adjustment for intra-electrode distance, and a distance spacing sensor may be used to generate a signal either to the operator or directly to the pulse generator so that voltage adjustments can be made in order to establish the desired electric field.
- an array as above described is selected and optionally mounted on a suitable carrier which can then be stereotaxically positioned in relationship to the patient so as to facilitate the accurate and rapid establishment of the electrode array in situ in the patient.
- a suitable carrier which can then be stereotaxically positioned in relationship to the patient so as to facilitate the accurate and rapid establishment of the electrode array in situ in the patient.
- acute placement of the electrodes will be made into the peripheral regions of the cavity remaining after surgical resection of a tumor mass.
- Electrode array geometry can be maintained by a support, while electrode placement and depth would be determined by the surgeon.
- the therapeutic agent will then be infused into the patient either systemically or by direct injection into the vasculature of the predetermined tissue region or directly into the tissue itself, or by methods as described in Application Serial No. 08/476,714.
- the function of the pulse or signal generator is to generate a predetermined electrical waveform which, when applied to the electrodes, results in the propagation of electric fields of the predetermined amplitude and duration through the tissue that is positioned between the electrodes.
- these waveforms are applied repeatedly so as to optimize the electropermeability effect.
- two elements are ordinarily controlled to provide the intended benefits: i) the electrical waveform parameters delivered by the signal generator, and ii) the electrical state of each individual electrode within the array during the delivery of the waveform.
- the electrical waveform parameters which can be controlled include the type of waveform, the signal amplitude, and the pulse duration. These individual parameters determine the characteristics of a single pulse. In certain embodiments it is desirable to vary these characteristics between pulses. Pulse-to-pulse variability dictates that one or more individual parameters, such as amplitude, be manipulated from one pulse to the next in order to increase safety or therapeutic efficacy.
- Figure 18 depicts a pulse train wherein a high amplitude pulse 46 is followed by a series of lower amplitude pulses 48.
- Pulse sequences determine the manner in which individual pulses are integrated. In this regard, the number of, and time interval between, individual pulses in a sequence is regulated, as well as the number of pulse sequences in a course of therapeutic treatment (e.g. 46, 46', 46" in Figure 18).
- Control of the electrical state of the individual electrodes involves a system capable of individually addressing electrodes within an array.
- One embodiment of such control would incorporate a high voltage switching device wherein the electrical state of each electrode is controlled by an individual switch.
- Each switch would have three settings: i) pulse positive (+), ii) pulse negative (-), and iii) open (i.e. off). Together these switches could be electrically activated in any of numerous possible combinations.
- an array of "tricells" can be pulsed in a "trigrid” pattern with only four channels (as depicted in Figure 11), system flexibility in establishing alternative array patterns suggests the use of individual switches for each electrode in the array.
- the integrated control of these and other elements of the invention can be accomplished by utilizing microprocessor or digital computer technologies.
- data pertaining to realtime waveform delivery can be digitized and acquired for evaluation and verification of proper system function. Desirably, such data could be stored within the local system until uploaded to a central computer for further use.
- Electric fields will be established within the target tissue by delivery of electrical waveforms to preselected electrodes.
- the parameters of the signal will define the electric field strength E (in kV/cm) within the tissue.
- E the electric field strength
- Each protocol and tissue will have its own characteristics which determine the critical field strength for optimum therapeutic effect. This tissue variation is due to cell size, membrane composition and the individual characteristics of the cell membrane itself. Generally, the required field strength varies inversely with the size of the cells contained within the tissue. Mammalian tissue generally requires field strengths of between approximately 0.2 kV/cm to 3 kV/cm for electroporation.
- the electrical waveform provided by the generator can be an exponentially decaying pulse, a square pulse, a unipolar oscillating pulse train or a bipolar oscillating pulse train. Square pulses are generally sufficient to implement the majority of techniques.
- the electric field strength can desirably be between 0.2 kV/cm to 20 kV/cm, more commonly 0.5 kV/cm to 3 kV/cm.
- the pulse duration can be from 100 nanoseconds to 100 milliseconds and there can be from 1 to 10,000 pulses per second.
- the waveform, strength and pulse duration will be dependent on the tissue in the predetermined region and the type of therapeutic agent that is to permeate the cells via electroporation.
- the present invention provides an apparatus and system for the transport and delivery of therapeutic agents in vivo to a predetermined region of tissue within the host.
- Such transport and delivery consists of, in part: i) the localized circulatory extravasation of systemically administered therapeutic agents; (ii) the local extracellular infusion of therapeutic agents; (iii) the distribution and concentration of therapeutic agent within the predetermined region of tissue; (iv) the electroporation of cell membranes within the predetermined region of tissue; and (v) the transport of the therapeutic agents into the cytosol of the electroporated cells within the predetermined region of tissue.
- one embodiment of the electrode array representing a single electrode cell (a tricell as depicted in Figure 4), is comprised of three individually addressable penetrating electrodes ordinarily of approximately uniform predetermined lengths, desirably of biologically compatible construction and with electrically nonconductive proximal regions and electrically conductive distal regions; such electrically conductive distal regions defining the effective electrode length.
- the effective electrode length of each individual electrode may be different and will be of a predetermined value in order to confine the electric field effects to the predetermined region for tissue treatment.
- Such predetermination of electrode length shall be of sufficient value as to assure appropriate consideration for the weakened electric field effects encountered at either end of the electrode, as depicted in Figure 2 (i.e. the field-fringe effect 33).
- the present invention also provides an efficient means of expanding the electrode array tricell, or any alternative cell design, into a multi-cell grid for controlled electric field propagation in an expanded cross sectional area of the predetermined region.
- a tricell as depicted in Figure 4 can be expanded in a multi-cell pattern (i.e., a "trigrid") to provide therapeutic coverage of the "X" and "Y" dimension of a predetermined treatment region which exceeds the linear dimension L (see Figure 10).
- the trigrid When compared to other electrode designs configured with the same L (see Figures 13, 14 and 15), the trigrid offers considerable advantages in uniformity of electric field coverage and efficiency when directly comparing the number of electrodes required to treat a given predetermined treatment region. This advantage is an important consideration in any clinical/surgical application.
- One benefit of this expansion into a trigrid is that once the basic tricell is established, each additional electrode placed in the array creates at least one and possibly two additional cells in the array grid.
- the manner in which the trigrid can be pulsed in a tricell-interlocking manner is the manner in which the trigrid can be pulsed in a tricell-interlocking manner, as depicted in Figure 12.
- This pattern provides complete therapeutic coverage of the predetermined treatment region with only three pulse combinations (see Figure 6), and requires only four electrode channels (see Figure 11) regardless of the number of electrodes in the complete array. Overall tissue trauma during surgery is thus minimized, a unique characteristic of the trigrid array.
- the optimal trigrid pattern and effective electrode length can be determined, thus defining the predetermined region targeted for treatment.
- these electrodes may be placed acutely for single treatment or chronically for a series of treatments to the same predetermined region in the patient.
- a localized hyperconductance of the extracellular fluids may be desirable in order to partially shunt or shift field intensities away from the electrode milieu and toward the more central portions of L in the predetermined region. This may be accomplished by direct injection of hyperconductive solutions by local injection, or by infusion through a hollow core in the electrode. Alternatively, in certain embodiments, such as electroporation, electrical pulse parameters determined to be of therapeutic benefit may be adapted in such a way as to initially induce localized increases in the conductance of the electrode milieu.
- One method of inducing such effect is a cascaded pulse sequence (see Figure 17) where applied voltages are cascaded from lower values initially 50, being progressively increased in each subsequent round 52, 54, and reaching optimal therapeutic pulse parameters in a final round of pulsing.
- electrically charged therapeutic agents are desirably distributed through and concentrated within the predetermined region by means of electrical waveforms delivered through the individually addressable electrodes of the present invention.
- the transmembrane delivery of therapeutic agent into the cytosol of the permeabilized cells is commonly believed to occur by diffusion.
- Electroosmosis may enhance this transmembrane delivery.
- electrical waveforms of a lesser intensity 48, 48' , 48" in Figure 18
- the electroporation waveforms after the electroporation waveforms have been delivered and before cell membrane resealing, in order to enhance the transport of the extracellular therapeutic agents into the cytosol of the electroporated cells.
- the following examples serve to illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.
- Example 1 Tumor model used in survival studies.
- the experimental brain tumor model employed in the following examples was the 9L gliosarcoma in the female Fischer rat.
- Tumor implants consisted of 200,000 9L gliosarcoma cells suspended in 2.3 ⁇ L of Dulbecco's Phosphate Buffered Saline with 2% rat serum. After anesthetization by intra peritoneal injection of a ketamine/xylazine mixture, the scalp was shaved and swabbed with Betadine ® solution. After placement in a stereotaxic apparatus, a 1cm incision was made in the scalp above bregma. A burr hole was drilled in the skull 1mm anterior and 3mm lateral of bregma.
- Example 2 Single Treatment - Triangle Electrode Array (Tricell).
- the rats were again anesthetized with an i.p. injection of a ketamine/xylazine mixture.
- the scalp was again disinfected with Betadine ® .
- Another incision was made in the scalp and the burr hole was located.
- An electrode array comprising three elongate rod electrodes oriented in an approximate equilateral triangle was then placed in the stereotactic arm. The array was then placed around the burr hole so that each electrode was approximately equidistant from the implant hole. New burr holes were drilled to accommodate the electrodes. The array was then lowered with the stereotaxic arm to a depth of 5mm.
- the x-axis represents days of survival and the y- axis represents the percentage of subject alive on the selected day.
- Figure 19 demonstrates, 120 days after implant 43% of the treated animals survived, and showed no outward signs of the presence of a tumor mass.
- the dashed line represents a control group which received no treatment.
- Example 3 Multiple Treatments - Triangle Electrode Array (Tricell)
- Example 2 The tumor model from Example 1 was again employed for these experiments. Animal subjects were treated on day eight post-implantation with the protocol outlined in Example 2 for the triangle electrode arrays. On day eleven, the animals were re-anesthetized and, after reopening the scalp and removing the bone wax plugs, the electrodes were lowered into the existing burr holes. The identical treatment procedure was then performed on the animal. Results: In Figure 20, a Kaplan-Meier survival chart illustrates the survival rates for the multiple treatment groups. Fifteen animals received the two treatment procedure as described. As Figure 20 demonstrates, 120 days after implant 87% of the treated animals survived, and showed no outward signs of the presence of a tumor mass. The dashed line represents a control group which received no treatment.
- the brains of six of the 13 surviving subjects were then prepared according to the histological procedure of Example 2. Pathological examination of the tissue sections revealed no residual tumor.
- Example 1 Four electrodes were arranged into two approximately equilateral triangles with sides of 3mm. The preparation procedure from example 3 was followed for each subject. The electrode array was lowered to a depth of 5 mm. The pulsing regimen was based on the trigrid pulsing pattern outlined in Figure 12.
- Tri-grid pulsing Thirty minutes after the injection of the bleomycin agent, the array was pulsed four times in each of three combinations with a magnitude of 300 volts (1 kV/cm based on electrode spacing) and a pulse duration of lOO ⁇ sec. The electrodes were pulsed so that each "cell” was configured with a single primary and two secondary electrodes. All four of the electrodes were active in each configuration, creating an interlocking triangle array.
- a Kaplan-Meier survival chart illustrates the survival rates for the animals treated as described. As Figure 21 demonstrates, 120 days after implant 75 % of the treated animals survived, and showed no outward signs of the presence of a tumor mass. The dashed line represents a control group which received no treatment.
- the brains of the six surviving subjects were then prepared according to the histological procedure of Example 2. Pathological examination of the tissue sections revealed no residual tumor.
- Example 2 Three control protocols were performed to compare with the treatment groups. All subjects were implanted according to the procedure outlined in Example 1. The first group of 35 rats received no treatment (Drug (D) -, Electrical Pulsing (EP) -). The second group of eight rats were treated on day eight post implant in accordance with the procedure of Example 2, except they did not receive the therapeutic agent (D-, EP+). The third group of eight rats were treated on day eight post implant in accordance with the procedure of Example 2, except they did not receive the electrical pulses (D + , EP-). Results: In Figure 22, a Kaplan-Meier survival chart illustrates the survival rates for the animals in the control protocols. As Figure 22 demonstrates, no animals from any of the control protocols survived beyond 32 days after implant. There was no significant difference in survival between any of the groups (D- EP-, D- EP+ , D + , EP-), demonstrating that both the therapeutic agent and the electrical pulse regimen are necessary for significant increase in survival.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP54633698A JP2001522274A (en) | 1997-04-24 | 1998-04-23 | Electrodes and electrode arrangement |
CA002287366A CA2287366A1 (en) | 1997-04-24 | 1998-04-23 | Electrodes and electrode arrays |
AU71515/98A AU734611B2 (en) | 1997-04-24 | 1998-04-23 | Electrodes and electrode arrays |
EP98918621A EP0973579A4 (en) | 1997-04-24 | 1998-04-23 | Electrodes and electrode arrays |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/845,553 US5873849A (en) | 1997-04-24 | 1997-04-24 | Electrodes and electrode arrays for generating electroporation inducing electrical fields |
US08/845,553 | 1997-04-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998047562A1 true WO1998047562A1 (en) | 1998-10-29 |
Family
ID=25295503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/008183 WO1998047562A1 (en) | 1997-04-24 | 1998-04-23 | Electrodes and electrode arrays |
Country Status (6)
Country | Link |
---|---|
US (2) | US5873849A (en) |
EP (1) | EP0973579A4 (en) |
JP (1) | JP2001522274A (en) |
AU (1) | AU734611B2 (en) |
CA (1) | CA2287366A1 (en) |
WO (1) | WO1998047562A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000035532A1 (en) | 1998-12-17 | 2000-06-22 | University Of South Florida | Nonpenetrating electroporation device |
WO2001043817A1 (en) | 1999-12-15 | 2001-06-21 | University Of South Florida | Electroporation device and method |
JP2002535100A (en) * | 1999-01-28 | 2002-10-22 | サイト パルス サイエンシズ、インコーポレイテッド | Delivery of macromolecules into cells |
US6778853B1 (en) | 1997-12-17 | 2004-08-17 | University Of South Florida | Electroporation device |
EP1515775A2 (en) * | 2002-05-07 | 2005-03-23 | SCHROEPPEL, Edward A. | Method and device for treating concer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy |
US6937890B2 (en) | 1998-12-17 | 2005-08-30 | University Of South Florida | Nonpenetrating electroporation device |
FR2872055A1 (en) | 2004-06-24 | 2005-12-30 | Yves Leon Scherman | Apparatus for transferring active principle molecules into tissue cells using one or two physical forces has two electrode needles and one or more injection needles |
FR2872056A1 (en) | 2004-06-24 | 2005-12-30 | Yves Scherman | Injection apparatus for active principles, comprises using a combination of needle and plate electrodes for enhanced penetration |
FR2880808A1 (en) | 2005-01-20 | 2006-07-21 | Yves Scherman | Active material e.g. nucleotide, delivering device for providing e.g. chemotherapy, has electric current generator, electrodes connected to respective terminals of current generator and injection needle centered between electrodes |
WO2008146075A1 (en) * | 2007-05-31 | 2008-12-04 | Biophox Gmbh & Co. Kg | Device for treating tumors |
US7742811B2 (en) | 2000-03-13 | 2010-06-22 | Onco Stim | Implantable device and method for the electrical treatment of cancer |
US8024048B2 (en) | 2000-03-13 | 2011-09-20 | Ionix Medical Inc. | Method and device for treating cancer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy |
EP2470255A1 (en) * | 2009-08-24 | 2012-07-04 | Ron L. Alterman | Apparatus for trans-cerebral electrophoresis and methods of use thereof |
US9211155B2 (en) | 2008-08-20 | 2015-12-15 | Prostacare Pty Ltd. | Non-thermal ablation system for treating BPH and other growths |
US11224474B2 (en) | 2018-02-28 | 2022-01-18 | Prostacare Pty Ltd | System for managing high impedance changes in a non-thermal ablation system for BPH |
US11457975B2 (en) | 2017-11-27 | 2022-10-04 | Prostacare Pty Ltd | Apparatus and a method for the treatment of a prostatic disease |
Families Citing this family (259)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5702359A (en) * | 1995-06-06 | 1997-12-30 | Genetronics, Inc. | Needle electrodes for mediated delivery of drugs and genes |
US5993434A (en) * | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
US6041252A (en) * | 1995-06-07 | 2000-03-21 | Ichor Medical Systems Inc. | Drug delivery system and method |
US5873849A (en) * | 1997-04-24 | 1999-02-23 | Ichor Medical Systems, Inc. | Electrodes and electrode arrays for generating electroporation inducing electrical fields |
US6216034B1 (en) | 1997-08-01 | 2001-04-10 | Genetronics, Inc. | Method of programming an array of needle electrodes for electroporation therapy of tissue |
US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
US6043066A (en) * | 1997-09-04 | 2000-03-28 | Mangano; Joseph A. | Cell separation using electric fields |
AUPO907697A0 (en) * | 1997-09-09 | 1997-10-02 | Day, Robert Edward | Chemical supplementation of bone |
US20050019921A1 (en) * | 2001-11-27 | 2005-01-27 | Orwar Owe E. | Method for combined sequential agent delivery and electroporation for cell structures and use thereof |
US7456012B2 (en) * | 1997-11-06 | 2008-11-25 | Cellectricon Ab | Method and apparatus for spatially confined electroporation |
US6135990A (en) * | 1997-12-17 | 2000-10-24 | University Of South Florida | Electroporation device and method |
US6208893B1 (en) | 1998-01-27 | 2001-03-27 | Genetronics, Inc. | Electroporation apparatus with connective electrode template |
US6009347A (en) * | 1998-01-27 | 1999-12-28 | Genetronics, Inc. | Electroporation apparatus with connective electrode template |
WO1999042156A1 (en) | 1998-02-24 | 1999-08-26 | Boston Scientific Limited | High flow rate dialysis catheters and related methods |
US6027488A (en) * | 1998-06-03 | 2000-02-22 | Genetronics, Inc. | Flow-through electroporation system for ex vivo gene therapy |
US20040229363A1 (en) * | 1998-06-24 | 2004-11-18 | Ed Nolan | High efficiency transfection based on low electric field strength, long pulse length |
CA2335888A1 (en) * | 1998-06-26 | 2000-01-06 | Genetronics, Inc. | Synergism of photodynamic and electropermeation effects on cell vitality as a novel cytotoxic agent |
EP2428250A1 (en) | 1998-07-13 | 2012-03-14 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
US6678556B1 (en) | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
EP1102608A4 (en) | 1998-07-13 | 2008-09-17 | Genetronics Inc | Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications |
US7922709B2 (en) * | 1998-07-13 | 2011-04-12 | Genetronics, Inc. | Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation |
AU747100B2 (en) | 1998-07-20 | 2002-05-09 | Ichor Medical Systems, Inc. | Electroporation electrodes |
US6319901B1 (en) | 1998-10-15 | 2001-11-20 | Ichor Medical Systems, Inc. | Methods for prolonging cell membrane permeability |
US6542776B1 (en) * | 1999-04-14 | 2003-04-01 | Transneuronix Inc. | Gastric stimulator apparatus and method for installing |
US6684104B2 (en) * | 1999-04-14 | 2004-01-27 | Transneuronix, Inc. | Gastric stimulator apparatus and method for installing |
US6256533B1 (en) * | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
US6300108B1 (en) * | 1999-07-21 | 2001-10-09 | The Regents Of The University Of California | Controlled electroporation and mass transfer across cell membranes |
US6539264B1 (en) | 1999-12-01 | 2003-03-25 | Vertis Neuroscience, Inc. | Percutaneous electrical therapy system with sharp point protection |
US6516226B1 (en) | 1999-12-01 | 2003-02-04 | Vertis Neuroscience, Inc. | Percutaneous electrical therapy system for minimizing electrode insertion discomfort |
US6556869B1 (en) | 1999-12-01 | 2003-04-29 | Vertis Neuroscience, Inc. | Electrode introducer for a percutaneous electrical therapy system |
US6912424B2 (en) * | 1999-12-01 | 2005-06-28 | Meagan, Medical, Inc. | Apparatus and method for coupling therapeutic and/or monitoring equipment to a patient |
US6560491B1 (en) | 1999-12-01 | 2003-05-06 | Vertis Neuroscience, Inc. | Percutaneous electrical therapy system providing electrode axial support |
US6493592B1 (en) | 1999-12-01 | 2002-12-10 | Vertis Neuroscience, Inc. | Percutaneous electrical therapy system with electrode position maintenance |
US6904324B2 (en) * | 1999-12-01 | 2005-06-07 | Meagan Medical, Inc. | Method and apparatus for deploying a percutaneous probe |
US6622051B1 (en) | 1999-12-01 | 2003-09-16 | Vertis Neuroscience, Inc. | Percutaneous electrical therapy system with electrode entry angle control |
US6542780B1 (en) * | 1999-12-01 | 2003-04-01 | Vertis Neuroscience, Inc. | Method and apparatus for electrically coupling a percutaneous probe |
US6522927B1 (en) | 1999-12-01 | 2003-02-18 | Vertis Neuroscience, Inc. | Electrode assembly for a percutaneous electrical therapy system |
US6549797B1 (en) | 1999-12-01 | 2003-04-15 | Vertis Neuroscience, Inc. | Electrode remover for a percutaneous electrical therapy system |
US6549810B1 (en) | 1999-12-01 | 2003-04-15 | Vertis Neuroscience, Inc. | Percutaneous electrical therapy system with electrode depth control |
US6714816B1 (en) * | 2000-02-22 | 2004-03-30 | University Of South Florida | Electroporation and electrophoresis system and method for achieving molecular penetration into cells in vivo |
US7756584B2 (en) * | 2000-07-13 | 2010-07-13 | Advanced Neuromodulation Systems, Inc. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
CA2416581A1 (en) * | 2000-07-25 | 2002-04-25 | Rita Medical Systems, Inc. | Apparatus for detecting and treating tumors using localized impedance measurement |
US6795728B2 (en) | 2001-08-17 | 2004-09-21 | Minnesota Medical Physics, Llc | Apparatus and method for reducing subcutaneous fat deposits by electroporation |
US6697670B2 (en) | 2001-08-17 | 2004-02-24 | Minnesota Medical Physics, Llc | Apparatus and method for reducing subcutaneous fat deposits by electroporation with improved comfort of patients |
US8251986B2 (en) | 2000-08-17 | 2012-08-28 | Angiodynamics, Inc. | Method of destroying tissue cells by eletroporation |
US6892099B2 (en) * | 2001-02-08 | 2005-05-10 | Minnesota Medical Physics, Llc | Apparatus and method for reducing subcutaneous fat deposits, virtual face lift and body sculpturing by electroporation |
US7118555B2 (en) * | 2000-09-21 | 2006-10-10 | Meagan Medical, Inc. | Method and apparatus for repositioning a percutaneous probe |
US6701190B2 (en) | 2000-10-10 | 2004-03-02 | Meagan Medical, Inc. | System and method for varying characteristics of electrical therapy |
US6671557B1 (en) | 2000-10-10 | 2003-12-30 | Meagan Medical, Inc. | System and method for providing percutaneous electrical therapy |
US7828827B2 (en) | 2002-05-24 | 2010-11-09 | Corium International, Inc. | Method of exfoliation of skin using closely-packed microstructures |
US7108681B2 (en) * | 2000-10-16 | 2006-09-19 | Corium International, Inc. | Microstructures for delivering a composition cutaneously to skin |
US7131987B2 (en) | 2000-10-16 | 2006-11-07 | Corium International, Inc. | Microstructures and method for treating and conditioning skin which cause less irritation during exfoliation |
US20050043726A1 (en) * | 2001-03-07 | 2005-02-24 | Mchale Anthony Patrick | Device II |
US6663820B2 (en) * | 2001-03-14 | 2003-12-16 | The Procter & Gamble Company | Method of manufacturing microneedle structures using soft lithography and photolithography |
DE20109099U1 (en) | 2001-05-30 | 2001-08-09 | Schoenfeld Andreas | Device for the treatment of tumors |
DE10129912A1 (en) * | 2001-06-21 | 2003-01-02 | Efmt Entwicklungs Und Forschun | needle electrode |
US20040204669A1 (en) * | 2001-07-05 | 2004-10-14 | Hofmann Gunter A. | Apparatus for electroporation mediated delivery for drugs and genes |
US6994706B2 (en) * | 2001-08-13 | 2006-02-07 | Minnesota Medical Physics, Llc | Apparatus and method for treatment of benign prostatic hyperplasia |
US7130697B2 (en) * | 2002-08-13 | 2006-10-31 | Minnesota Medical Physics Llc | Apparatus and method for the treatment of benign prostatic hyperplasia |
USRE42016E1 (en) | 2001-08-13 | 2010-12-28 | Angiodynamics, Inc. | Apparatus and method for the treatment of benign prostatic hyperplasia |
US20040087992A1 (en) * | 2002-08-09 | 2004-05-06 | Vladimir Gartstein | Microstructures for delivering a composition cutaneously to skin using rotatable structures |
WO2003047684A2 (en) * | 2001-12-04 | 2003-06-12 | University Of Southern California | Method for intracellular modifications within living cells using pulsed electric fields |
JP4511189B2 (en) * | 2002-02-12 | 2010-07-28 | セレクトリコン アーベー | System and method for rapidly changing the solution environment around a sensor |
US8209006B2 (en) * | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
US7245963B2 (en) * | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
EP1480720B1 (en) * | 2002-03-07 | 2018-08-22 | Inovio Pharmaceuticals, Inc. | Electrode assembly for constant-current electroporation |
EP1494720A4 (en) * | 2002-03-22 | 2009-12-30 | Univ California | Method and apparatus for using an electromagnetic field in cellular transplantation |
US6912417B1 (en) | 2002-04-05 | 2005-06-28 | Ichor Medical Systmes, Inc. | Method and apparatus for delivery of therapeutic agents |
US20060089674A1 (en) | 2002-04-16 | 2006-04-27 | Walters Richard E | Method of treating biological materials with translating electrical fields and electrode polarity reversal |
DE60324417D1 (en) * | 2002-05-23 | 2008-12-11 | Gendel Ltd | ablation |
AU2003278461A1 (en) | 2002-10-16 | 2004-05-04 | Cellectricon Ab | Nanoelectrodes and nanotips for recording transmembrane currents in a plurality of cells |
CA2508800A1 (en) * | 2002-12-11 | 2004-06-24 | Proteus Biomedical, Inc. | Method and system for monitoring and treating hemodynamic parameters |
US7204798B2 (en) * | 2003-01-24 | 2007-04-17 | Proteus Biomedical, Inc. | Methods and systems for measuring cardiac parameters |
US7578954B2 (en) * | 2003-02-24 | 2009-08-25 | Corium International, Inc. | Method for manufacturing microstructures having multiple microelements with through-holes |
CA2432810A1 (en) | 2003-06-19 | 2004-12-19 | Andres M. Lozano | Method of treating depression, mood disorders and anxiety disorders by brian infusion |
GB2403148C2 (en) | 2003-06-23 | 2013-02-13 | Microsulis Ltd | Radiation applicator |
JP2007501067A (en) * | 2003-08-01 | 2007-01-25 | ノーススター ニューロサイエンス インコーポレイテッド | Apparatus and method for applying neural stimulation to patient |
US8298222B2 (en) | 2003-12-24 | 2012-10-30 | The Regents Of The University Of California | Electroporation to deliver chemotherapeutics and enhance tumor regression |
AU2004311842C1 (en) | 2003-12-24 | 2011-01-06 | The Regents Of The University Of California | Tissue ablation with irreversible electroporation |
GB0402569D0 (en) * | 2004-02-05 | 2004-03-10 | Neurodan As | Nerve and/or muscle stimulation electrodes |
CN1997423B (en) | 2004-03-08 | 2012-10-03 | 艾科医疗系统公司 | Improved apparatus for electrically mediated delivery of therapeutic agents |
WO2005094526A2 (en) * | 2004-03-24 | 2005-10-13 | Corium International, Inc. | Transdermal delivery device |
JP4443278B2 (en) * | 2004-03-26 | 2010-03-31 | テルモ株式会社 | Catheter with expansion body |
JP5065005B2 (en) | 2004-04-01 | 2012-10-31 | ザ ジェネラル ホスピタル コーポレイション | Method and apparatus for dermatological treatment and tissue remodeling |
US7720549B2 (en) * | 2004-04-06 | 2010-05-18 | Oncostim, Inc. | Partially implantable system for the electrical treatment of abnormal tissue growth |
US20050222646A1 (en) * | 2004-04-06 | 2005-10-06 | Kai Kroll | Method and device for treating cancer with modified output electrical therapy |
EP1750800A1 (en) * | 2004-04-30 | 2007-02-14 | Advanced Neuromodulation Systems, Inc. | Method of treating mood disorders and/or anxiety disorders by brain stimulation |
US7706873B2 (en) * | 2004-05-05 | 2010-04-27 | Mario Ammirati | System and method for controlled delivery of a therapeutic agent to a target location within an internal body tissue |
GB2415630C2 (en) | 2004-07-02 | 2007-03-22 | Microsulis Ltd | Radiation applicator and method of radiating tissue |
EP1799101A4 (en) * | 2004-09-02 | 2008-11-19 | Proteus Biomedical Inc | Methods and apparatus for tissue activation and monitoring |
WO2006105474A2 (en) * | 2005-03-31 | 2006-10-05 | Proteus Biomedical, Inc. | Automated optimization of multi-electrode pacing for cardiac resynchronization |
GB0502384D0 (en) * | 2005-02-04 | 2005-03-16 | Instrumedical Ltd | Electro-surgical needle apparatus |
JP2008535538A (en) * | 2005-03-01 | 2008-09-04 | ファンクショナル ニューロサイエンス インコーポレイテッド | Methods for treating depression, mood disorders and anxiety disorders using neuromodulation |
WO2006094072A2 (en) * | 2005-03-01 | 2006-09-08 | Functional Neuroscience Inc. | Method of treating cognitive disorders using neuromodulation |
EP1698907A1 (en) * | 2005-03-04 | 2006-09-06 | Cardiatis Société Anonyme | Interventional medical device for use in MRI |
US20060264752A1 (en) * | 2005-04-27 | 2006-11-23 | The Regents Of The University Of California | Electroporation controlled with real time imaging |
EP1899001B1 (en) * | 2005-06-08 | 2017-10-25 | Novocure Limited | Apparatus for treating cancer with electric fields that are guided to desired locations within a body |
US20060293725A1 (en) * | 2005-06-24 | 2006-12-28 | Boris Rubinsky | Methods and systems for treating fatty tissue sites using electroporation |
US20060293731A1 (en) * | 2005-06-24 | 2006-12-28 | Boris Rubinsky | Methods and systems for treating tumors using electroporation |
US20060293730A1 (en) | 2005-06-24 | 2006-12-28 | Boris Rubinsky | Methods and systems for treating restenosis sites using electroporation |
US8114070B2 (en) * | 2005-06-24 | 2012-02-14 | Angiodynamics, Inc. | Methods and systems for treating BPH using electroporation |
WO2007004831A1 (en) * | 2005-06-30 | 2007-01-11 | Lg Electronics Inc. | Method and apparatus for encoding and decoding an audio signal |
GB2434314B (en) | 2006-01-03 | 2011-06-15 | Microsulis Ltd | Microwave applicator with dipole antenna |
WO2007021804A2 (en) * | 2005-08-12 | 2007-02-22 | Proteus Biomedical, Inc. | Evaluation of depolarization wave conduction velocity |
US20070142885A1 (en) * | 2005-11-29 | 2007-06-21 | Reliant Technologies, Inc. | Method and Apparatus for Micro-Needle Array Electrode Treatment of Tissue |
US20100204766A1 (en) * | 2005-12-22 | 2010-08-12 | Mark Zdeblick | Implantable integrated circuit |
US20070156135A1 (en) * | 2006-01-03 | 2007-07-05 | Boris Rubinsky | System and methods for treating atrial fibrillation using electroporation |
JP5059786B2 (en) * | 2006-02-11 | 2012-10-31 | ジェネトロニクス,インコーポレイティド | Apparatus and method for single needle in vivo electroporation |
WO2007117651A2 (en) * | 2006-04-07 | 2007-10-18 | University Of South Florida | Passive electric field focus system for in vivo and in vitro applications |
DK2032057T3 (en) * | 2006-06-12 | 2010-02-08 | Region Hovedstaden V Herlev Ho | Electrode insertion device |
EP2076313A4 (en) * | 2006-10-16 | 2012-07-25 | Univ California | Gels with predetermined conductivity used in irreversible electroporation of tissue |
US20080132884A1 (en) * | 2006-12-01 | 2008-06-05 | Boris Rubinsky | Systems for treating tissue sites using electroporation |
US20080132885A1 (en) * | 2006-12-01 | 2008-06-05 | Boris Rubinsky | Methods for treating tissue sites using electroporation |
CA2676221C (en) * | 2007-01-22 | 2016-12-20 | Corium International, Inc. | Applicators for microneedles |
US7655004B2 (en) | 2007-02-15 | 2010-02-02 | Ethicon Endo-Surgery, Inc. | Electroporation ablation apparatus, system, and method |
EP2146689B1 (en) | 2007-04-16 | 2020-08-12 | Corium, Inc. | Solvent-cast microneedle arrays containing active |
US8694105B2 (en) | 2007-07-10 | 2014-04-08 | Sapiens Steering Brain Stimulation B.V. | Neurostimulation system having a controller for controlling the supply of electrical pulses |
US20090088703A1 (en) * | 2007-09-13 | 2009-04-02 | Kouros Azar | Skin treatment system and method |
WO2009048607A1 (en) | 2007-10-10 | 2009-04-16 | Corium International, Inc. | Vaccine delivery via microneedle arrays |
JP5178132B2 (en) * | 2007-10-11 | 2013-04-10 | キヤノン株式会社 | Image processing system and image processing method |
US20100298759A1 (en) * | 2007-10-11 | 2010-11-25 | Region Hovedstaden V/Herlev Hospital | electroporation device for improved electrical field control |
WO2009073891A1 (en) * | 2007-12-07 | 2009-06-11 | Northstar Neuroscience, Inc. | Systems and methods for providing targeted neural stimulation therapy to address neurological disorders, including neuropyschiatric and neuropyschological disorders |
EP4328297A2 (en) | 2008-01-17 | 2024-02-28 | Inovio Pharmaceuticals, Inc. | Variable current density single needle electroporation system and method |
US8473069B2 (en) * | 2008-02-28 | 2013-06-25 | Proteus Digital Health, Inc. | Integrated circuit implementation and fault control system, device, and method |
US20090247933A1 (en) * | 2008-03-27 | 2009-10-01 | The Regents Of The University Of California; Angiodynamics, Inc. | Balloon catheter method for reducing restenosis via irreversible electroporation |
US20100004623A1 (en) * | 2008-03-27 | 2010-01-07 | Angiodynamics, Inc. | Method for Treatment of Complications Associated with Arteriovenous Grafts and Fistulas Using Electroporation |
US8926606B2 (en) * | 2009-04-09 | 2015-01-06 | Virginia Tech Intellectual Properties, Inc. | Integration of very short electric pulses for minimally to noninvasive electroporation |
US9867652B2 (en) | 2008-04-29 | 2018-01-16 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
US10245098B2 (en) | 2008-04-29 | 2019-04-02 | Virginia Tech Intellectual Properties, Inc. | Acute blood-brain barrier disruption using electrical energy based therapy |
US9198733B2 (en) * | 2008-04-29 | 2015-12-01 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for electroporation-based therapies |
CA2722296A1 (en) | 2008-04-29 | 2009-11-05 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation to create tissue scaffolds |
US9283051B2 (en) | 2008-04-29 | 2016-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
US8992517B2 (en) * | 2008-04-29 | 2015-03-31 | Virginia Tech Intellectual Properties Inc. | Irreversible electroporation to treat aberrant cell masses |
US10117707B2 (en) | 2008-04-29 | 2018-11-06 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US10702326B2 (en) | 2011-07-15 | 2020-07-07 | Virginia Tech Intellectual Properties, Inc. | Device and method for electroporation based treatment of stenosis of a tubular body part |
US10272178B2 (en) | 2008-04-29 | 2019-04-30 | Virginia Tech Intellectual Properties Inc. | Methods for blood-brain barrier disruption using electrical energy |
US11272979B2 (en) | 2008-04-29 | 2022-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US10238447B2 (en) | 2008-04-29 | 2019-03-26 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
US11254926B2 (en) | 2008-04-29 | 2022-02-22 | Virginia Tech Intellectual Properties, Inc. | Devices and methods for high frequency electroporation |
WO2009137800A2 (en) * | 2008-05-09 | 2009-11-12 | Angiodynamics, Inc. | Electroporation device and method |
US20090287266A1 (en) * | 2008-05-13 | 2009-11-19 | Mark Zdeblick | High-voltage tolerant multiplex multi-electrode stimulation systems and methods for using the same |
US9173704B2 (en) * | 2008-06-20 | 2015-11-03 | Angiodynamics, Inc. | Device and method for the ablation of fibrin sheath formation on a venous catheter |
US9681909B2 (en) * | 2008-06-23 | 2017-06-20 | Angiodynamics, Inc. | Treatment devices and methods |
US8888792B2 (en) | 2008-07-14 | 2014-11-18 | Ethicon Endo-Surgery, Inc. | Tissue apposition clip application devices and methods |
WO2010056438A2 (en) | 2008-11-13 | 2010-05-20 | Proteus Biomedical, Inc. | Shielded stimulation and sensing system and method |
WO2010057063A2 (en) * | 2008-11-13 | 2010-05-20 | Proteus Biomedical, Inc. | Pacing and stimulation system, device and method |
US7974705B2 (en) * | 2008-11-13 | 2011-07-05 | Proteus Biomedical, Inc. | Multiplexed multi-electrode neurostimulation devices |
EP2346391A4 (en) * | 2008-11-18 | 2012-08-15 | Proteus Biomedical Inc | Sensing system, device, and method for therapy modulation |
US8157834B2 (en) | 2008-11-25 | 2012-04-17 | Ethicon Endo-Surgery, Inc. | Rotational coupling device for surgical instrument with flexible actuators |
WO2010065465A2 (en) * | 2008-12-02 | 2010-06-10 | Proteus Biomedical, Inc. | Analyzer compatible communication protocol |
US20100152725A1 (en) * | 2008-12-12 | 2010-06-17 | Angiodynamics, Inc. | Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation |
US8361066B2 (en) | 2009-01-12 | 2013-01-29 | Ethicon Endo-Surgery, Inc. | Electrical ablation devices |
WO2010085765A2 (en) * | 2009-01-23 | 2010-07-29 | Moshe Meir H | Therapeutic energy delivery device with rotational mechanism |
US8231603B2 (en) * | 2009-02-10 | 2012-07-31 | Angiodynamics, Inc. | Irreversible electroporation and tissue regeneration |
US20100240995A1 (en) * | 2009-03-17 | 2010-09-23 | Bioelectromed Corp. | System and method for treating tumors |
US11638603B2 (en) | 2009-04-09 | 2023-05-02 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
US11382681B2 (en) | 2009-04-09 | 2022-07-12 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of high frequency electrical pulses for non-thermal ablation |
US8798705B2 (en) | 2009-04-14 | 2014-08-05 | Old Dominion University Research Foundation | Medical instrument for delivery of high voltage pulses and method of delivering the same |
WO2010124255A2 (en) * | 2009-04-24 | 2010-10-28 | Corium International, Inc. | Methods for manufacturing microprojection arrays |
USD630321S1 (en) | 2009-05-08 | 2011-01-04 | Angio Dynamics, Inc. | Probe handle |
WO2010138919A2 (en) | 2009-05-28 | 2010-12-02 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
WO2011011736A2 (en) | 2009-07-23 | 2011-01-27 | Proteus Biomedical, Inc. | Solid-state thin film capacitor |
GB2474233A (en) | 2009-10-06 | 2011-04-13 | Uk Investments Associates Llc | Cooling pump comprising a detachable head portion |
US20110098704A1 (en) | 2009-10-28 | 2011-04-28 | Ethicon Endo-Surgery, Inc. | Electrical ablation devices |
US20110118732A1 (en) | 2009-11-19 | 2011-05-19 | The Regents Of The University Of California | Controlled irreversible electroporation |
US9028483B2 (en) | 2009-12-18 | 2015-05-12 | Ethicon Endo-Surgery, Inc. | Surgical instrument comprising an electrode |
JP6327852B2 (en) | 2010-05-04 | 2018-05-23 | コリウム インターナショナル, インコーポレイテッド | Methods and devices for transdermal delivery of parathyroid hormone using microprojection arrays |
US9700368B2 (en) | 2010-10-13 | 2017-07-11 | Angiodynamics, Inc. | System and method for electrically ablating tissue of a patient |
US8718770B2 (en) | 2010-10-21 | 2014-05-06 | Medtronic, Inc. | Capture threshold measurement for selection of pacing vector |
US20130296995A1 (en) * | 2010-10-22 | 2013-11-07 | Glostrup Hospital | Method For Treating A Tissue Region With An Electric Field |
US10131900B2 (en) | 2010-12-15 | 2018-11-20 | Old Dominion University Research Foundation | Electroporation-induced electrosensitization |
WO2012088149A2 (en) | 2010-12-20 | 2012-06-28 | Virginia Tech Intellectual Properties, Inc. | High-frequency electroporation for cancer therapy |
US9233241B2 (en) * | 2011-02-28 | 2016-01-12 | Ethicon Endo-Surgery, Inc. | Electrical ablation devices and methods |
US9254169B2 (en) | 2011-02-28 | 2016-02-09 | Ethicon Endo-Surgery, Inc. | Electrical ablation devices and methods |
WO2012125785A1 (en) | 2011-03-17 | 2012-09-20 | Ethicon Endo-Surgery, Inc. | Hand held surgical device for manipulating an internal magnet assembly within a patient |
US8355784B2 (en) | 2011-05-13 | 2013-01-15 | Medtronic, Inc. | Dynamic representation of multipolar leads in a programmer interface |
US9457183B2 (en) | 2011-06-15 | 2016-10-04 | Tripep Ab | Injection needle and device |
US9078665B2 (en) | 2011-09-28 | 2015-07-14 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
US9414881B2 (en) | 2012-02-08 | 2016-08-16 | Angiodynamics, Inc. | System and method for increasing a target zone for electrical ablation |
US9427255B2 (en) | 2012-05-14 | 2016-08-30 | Ethicon Endo-Surgery, Inc. | Apparatus for introducing a steerable camera assembly into a patient |
US9078662B2 (en) | 2012-07-03 | 2015-07-14 | Ethicon Endo-Surgery, Inc. | Endoscopic cap electrode and method for using the same |
US9144459B2 (en) | 2012-07-19 | 2015-09-29 | Cook Medical Technologies Llc | Endoscopic ultrasound ablation needle |
US9545290B2 (en) | 2012-07-30 | 2017-01-17 | Ethicon Endo-Surgery, Inc. | Needle probe guide |
US10314649B2 (en) | 2012-08-02 | 2019-06-11 | Ethicon Endo-Surgery, Inc. | Flexible expandable electrode and method of intraluminal delivery of pulsed power |
US9277957B2 (en) | 2012-08-15 | 2016-03-08 | Ethicon Endo-Surgery, Inc. | Electrosurgical devices and methods |
EP2911736A4 (en) * | 2012-10-25 | 2016-06-15 | Oncosec Medical Inc | Electroporation device |
MX2015008157A (en) | 2012-12-21 | 2016-02-22 | Corium Int Inc | Microarray for delivery of therapeutic agent and methods of use. |
US10098527B2 (en) | 2013-02-27 | 2018-10-16 | Ethidcon Endo-Surgery, Inc. | System for performing a minimally invasive surgical procedure |
ES2921481T3 (en) | 2013-03-12 | 2022-08-26 | Corium Inc | Microprojection applicators |
EP2968751B1 (en) | 2013-03-15 | 2022-11-30 | Corium, Inc. | Multiple impact microprojection applicators |
CA2903763C (en) | 2013-03-15 | 2021-11-16 | Corium International, Inc. | Microarray with polymer-free microstructures, methods of making, and methods of use |
ES2761580T3 (en) | 2013-03-15 | 2020-05-20 | Corium Inc | Microarrays for therapeutic agent delivery, methods of use and manufacturing methods |
EP2968118B1 (en) | 2013-03-15 | 2022-02-09 | Corium, Inc. | Microarray for delivery of therapeutic agent and methods of use |
EP3290082A3 (en) | 2013-06-03 | 2018-06-06 | Pulse Biosciences, Inc. | Methods and devices for stimulating an immune response using nanosecond pulsed electric fields |
EP3030185B1 (en) * | 2013-08-06 | 2023-05-10 | Memorial Sloan Kettering Cancer Center | System and computer-accessible medium for in-vivo tissue ablation and/or damage |
CN103555574A (en) * | 2013-11-11 | 2014-02-05 | 苏州文曲生物微系统有限公司 | Flow-type electric punching device |
US10166321B2 (en) | 2014-01-09 | 2019-01-01 | Angiodynamics, Inc. | High-flow port and infusion needle systems |
AU2015236341B2 (en) | 2014-03-24 | 2020-03-05 | Old Dominion University Research Foundation | Expandable catheter devices electrode array |
EP3143124A4 (en) | 2014-05-12 | 2018-01-17 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
EP3188714A1 (en) | 2014-09-04 | 2017-07-12 | Corium International, Inc. | Microstructure array, methods of making, and methods of use |
WO2016089781A1 (en) | 2014-12-01 | 2016-06-09 | Electroblate, Inc. | Nanoelectroablation control and vaccination |
WO2016100325A1 (en) | 2014-12-15 | 2016-06-23 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
JP2018520817A (en) | 2015-05-15 | 2018-08-02 | クリアイット エルエルシーClearit, Llc | Tattoo removal system and method using low temperature plasma |
US10857093B2 (en) | 2015-06-29 | 2020-12-08 | Corium, Inc. | Microarray for delivery of therapeutic agent, methods of use, and methods of making |
WO2017139253A1 (en) * | 2016-02-08 | 2017-08-17 | Vomaris Innovations, Inc. | Composite bioelectric devices and methods of use |
JP6910075B2 (en) | 2016-03-28 | 2021-07-28 | イコル メディカル システムズ,インク. | Methods and devices for delivery of therapeutic agents |
US10821283B2 (en) * | 2016-04-04 | 2020-11-03 | Novocure Gmbh | Reducing motility of cancer cells using tumor treating fields (TTFields) |
US10538786B2 (en) | 2016-04-13 | 2020-01-21 | Janssen Pharmaceuticals, Inc. | Recombinant arterivirus replicon systems and uses thereof |
IT201600068691A1 (en) * | 2016-07-01 | 2018-01-01 | Igea S P A | HANDLING AND CONTROL SYSTEM FOR EXPANDABLE ELECTRODES OF A HANDPIECE USED IN AN ELECTRO-PORTION PROCESS |
JP7382230B2 (en) | 2016-10-17 | 2023-11-16 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | Recombinant viral replicon system and its use |
US10905492B2 (en) | 2016-11-17 | 2021-02-02 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
KR102655641B1 (en) | 2016-12-05 | 2024-04-05 | 얀센 파마슈티칼즈, 인코포레이티드 | Compositions and methods for enhancing gene expression |
US11045648B2 (en) | 2017-11-14 | 2021-06-29 | Boston Scientific Scimed, Inc. | Irreversible electroporation through a combination of substance injection and electrical field application |
US11607537B2 (en) | 2017-12-05 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | Method for treating neurological disorders, including tumors, with electroporation |
US11389531B2 (en) | 2017-12-19 | 2022-07-19 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines |
US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
EP3727445B1 (en) | 2017-12-19 | 2023-08-16 | Janssen Sciences Ireland Unlimited Company | Hepatitis b virus (hbv) vaccines and uses thereof |
AU2018389786A1 (en) | 2017-12-19 | 2020-06-18 | Bavarian Nordic A/S | Methods and compositions for inducing an immune response against hepatitis B virus (HBV) |
EA202091513A1 (en) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | VACCINES AGAINST HEPATITIS B VIRUS (HBV) AND THEIR APPLICATION |
JP2021511318A (en) | 2018-01-19 | 2021-05-06 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | Induction and enhancement of immune response using recombinant replicon system |
CN111615371B (en) | 2018-01-23 | 2024-02-27 | 波士顿科学国际有限公司 | Enhanced needle array and treatment for tumor ablation |
US11925405B2 (en) | 2018-03-13 | 2024-03-12 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
US11311329B2 (en) | 2018-03-13 | 2022-04-26 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for immunotherapy based treatments using non-thermal ablation techniques |
WO2020094622A1 (en) * | 2018-11-05 | 2020-05-14 | Region Hovedstaden V/Herlev Hospital | An electrode assembly for improved electric field distribution |
KR20210104780A (en) * | 2018-12-19 | 2021-08-25 | 클리어잇 엘엘씨 | Tattoo Removal Systems and Methods Using an Applied Electric Field |
TWI772823B (en) | 2019-06-18 | 2022-08-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators |
WO2020255014A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Recombinant interleukin 12 construct and uses thereof |
CA3141003A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pd-l1 inhibitors |
WO2020255013A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being amide derivatives |
WO2020255022A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and aminopyridine derivatives as hpk1 inhibitors |
WO2020255010A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines |
WO2020255042A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and a pyrimidine derivative |
US20220305117A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai |
EP3986454A1 (en) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody |
WO2020255016A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
WO2020255015A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
WO2020255039A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives |
WO2020255018A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Hepatitis b virus (hbv) vaccines and uses thereof |
WO2020255019A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and a quinazoline derivative |
US20220305114A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and small molecule pdl1 or pd1 inhibitor |
WO2020255035A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyrimidine derivatives |
WO2020255017A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
MA56533A (en) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Co | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND ANTI-PD-1 ANTIBODIES |
WO2020254876A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Virus-like particle delivery of hepatitis b virus (hbv) vaccines |
CN114340663A (en) | 2019-06-18 | 2022-04-12 | 爱尔兰詹森科学公司 | Combination of Hepatitis B Virus (HBV) vaccine and HBV-targeted RNAi |
US20220305118A1 (en) | 2019-06-20 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines |
AU2020295807A1 (en) | 2019-06-20 | 2022-02-17 | Janssen Sciences Ireland Unlimited Company | Lipid nanoparticle or liposome delivery of hepatitis B virus (HBV) vaccines |
US11950835B2 (en) | 2019-06-28 | 2024-04-09 | Virginia Tech Intellectual Properties, Inc. | Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy |
CN114945338A (en) | 2019-10-15 | 2022-08-26 | 波士顿科学国际有限公司 | Control system and user interface for an ablation system |
US20210196967A1 (en) * | 2019-12-31 | 2021-07-01 | Novocure Gmbh | Methods, systems, and apparatuses for managing temperatures induced by alternating fields |
JP2023533528A (en) | 2020-07-08 | 2023-08-03 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | RNA replicon vaccine against HBV |
US11771373B2 (en) | 2020-11-09 | 2023-10-03 | Biosense Webster (Israel) Ltd. | Staggered electrode arrangements for electrophysiological sensing |
TW202245809A (en) | 2020-12-18 | 2022-12-01 | 美商詹森藥物公司 | Combination therapy for treating hepatitis b virus infection |
WO2022146654A1 (en) | 2020-12-28 | 2022-07-07 | Janssen Pharmaceuticals, Inc. | Transcription activator-like effector nucleases (talens) targeting hbv |
WO2023233290A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Sciences Ireland Unlimited Company | Rnai agents targeting pd-l1 |
CN115102530B (en) * | 2022-08-29 | 2023-09-29 | 赛福凯尔(绍兴)医疗科技有限公司 | Electric field generating device and system for inhibiting tumor cells |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3991755A (en) | 1973-07-27 | 1976-11-16 | Medicon, Inc. | Iontophoresis apparatus for applying local anesthetics |
US4141359A (en) | 1976-08-16 | 1979-02-27 | University Of Utah | Epidermal iontophoresis device |
US4250878A (en) | 1978-11-22 | 1981-02-17 | Motion Control, Inc. | Non-invasive chemical species delivery apparatus and method |
US4398545A (en) | 1979-10-10 | 1983-08-16 | Cyclotechnical Medical Industries, Inc. | Pain-blocking bandage |
US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
US5389069A (en) | 1988-01-21 | 1995-02-14 | Massachusetts Institute Of Technology | Method and apparatus for in vivo electroporation of remote cells and tissue |
US5439440A (en) | 1993-04-01 | 1995-08-08 | Genetronics, Inc. | Electroporation system with voltage control feedback for clinical applications |
US5468223A (en) | 1992-11-30 | 1995-11-21 | C.N.R.S. Paris | Electrochemotherapy |
US5704908A (en) * | 1996-10-10 | 1998-01-06 | Genetronics, Inc. | Electroporation and iontophoresis catheter with porous balloon |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3957053A (en) * | 1975-03-03 | 1976-05-18 | Yen Kong Woo | Detachably connected acupuncture needles |
US4381789A (en) * | 1979-11-20 | 1983-05-03 | Siemens Aktiengesellschaft | Electrode system |
US4837049A (en) * | 1986-06-17 | 1989-06-06 | Alfred E. Mann Foundation For Scientific Research | Method of making an electrode array |
US5128257A (en) * | 1987-08-31 | 1992-07-07 | Baer Bradford W | Electroporation apparatus and process |
US5547467A (en) * | 1988-01-21 | 1996-08-20 | Massachusettes Institute Of Technology | Method for rapid temporal control of molecular transport across tissue |
ATE131081T1 (en) * | 1988-01-21 | 1995-12-15 | Massachusetts Inst Technology | MOLECULAR TRANSPORT THROUGH TISSUES USING ELECTROPORATION. |
US5749847A (en) * | 1988-01-21 | 1998-05-12 | Massachusetts Institute Of Technology | Delivery of nucleotides into organisms by electroporation |
CS275292B2 (en) * | 1989-02-22 | 1992-02-19 | Cvut Fakulta Elektrotechnick | Private rehabilitation apparatus with ion transcutaneous acceleration |
US5215088A (en) * | 1989-11-07 | 1993-06-01 | The University Of Utah | Three-dimensional electrode device |
US5545130A (en) * | 1992-04-08 | 1996-08-13 | Genetronics, Inc. | Flow through electroporation method |
US5501662A (en) * | 1992-05-22 | 1996-03-26 | Genetronics, Inc. | Implantable electroporation method and apparatus for drug and gene delivery |
US5507724A (en) * | 1992-07-01 | 1996-04-16 | Genetronics, Inc. | Electroporation and iontophoresis apparatus and method for insertion of drugs and genes into cells |
US5304120A (en) * | 1992-07-01 | 1994-04-19 | Btx Inc. | Electroporation method and apparatus for insertion of drugs and genes into endothelial cells |
US5464386A (en) * | 1992-08-17 | 1995-11-07 | Genetronics, Inc. | Transdermal drug delivery by electroincorporation of vesicles |
US5688233A (en) * | 1992-08-17 | 1997-11-18 | Genetronics, Inc. | Electronincorporation enhanced transdermal delivery of molecules |
US5462520A (en) * | 1992-08-17 | 1995-10-31 | Genetronics, Inc. | Transsurface drug delivery by electrofusion of microbubbles to the tissue surface |
US5298017A (en) * | 1992-12-29 | 1994-03-29 | Alza Corporation | Layered electrotransport drug delivery system |
FR2703253B1 (en) * | 1993-03-30 | 1995-06-23 | Centre Nat Rech Scient | APPLICATOR OF ELECTRIC PULSES FOR TREATING BIOLOGICAL TISSUES. |
US5702359A (en) * | 1995-06-06 | 1997-12-30 | Genetronics, Inc. | Needle electrodes for mediated delivery of drugs and genes |
US5993434A (en) * | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
AU682515B2 (en) * | 1993-06-08 | 1997-10-09 | Hisamitsu Pharmaceutical Co., Inc. | Iontophoresis system |
IL108775A (en) * | 1994-02-25 | 2003-09-17 | Univ Ramot | Method for efficient incorporation of molecules into cells |
US5873849A (en) * | 1997-04-24 | 1999-02-23 | Ichor Medical Systems, Inc. | Electrodes and electrode arrays for generating electroporation inducing electrical fields |
-
1997
- 1997-04-24 US US08/845,553 patent/US5873849A/en not_active Expired - Lifetime
-
1998
- 1998-04-23 AU AU71515/98A patent/AU734611B2/en not_active Ceased
- 1998-04-23 WO PCT/US1998/008183 patent/WO1998047562A1/en not_active Application Discontinuation
- 1998-04-23 JP JP54633698A patent/JP2001522274A/en not_active Ceased
- 1998-04-23 EP EP98918621A patent/EP0973579A4/en not_active Withdrawn
- 1998-04-23 CA CA002287366A patent/CA2287366A1/en not_active Abandoned
- 1998-11-09 US US09/188,627 patent/US6278895B1/en not_active Expired - Lifetime
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3991755A (en) | 1973-07-27 | 1976-11-16 | Medicon, Inc. | Iontophoresis apparatus for applying local anesthetics |
US4141359A (en) | 1976-08-16 | 1979-02-27 | University Of Utah | Epidermal iontophoresis device |
US4250878A (en) | 1978-11-22 | 1981-02-17 | Motion Control, Inc. | Non-invasive chemical species delivery apparatus and method |
US4398545A (en) | 1979-10-10 | 1983-08-16 | Cyclotechnical Medical Industries, Inc. | Pain-blocking bandage |
US5389069A (en) | 1988-01-21 | 1995-02-14 | Massachusetts Institute Of Technology | Method and apparatus for in vivo electroporation of remote cells and tissue |
US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
US5468223A (en) | 1992-11-30 | 1995-11-21 | C.N.R.S. Paris | Electrochemotherapy |
US5439440A (en) | 1993-04-01 | 1995-08-08 | Genetronics, Inc. | Electroporation system with voltage control feedback for clinical applications |
US5704908A (en) * | 1996-10-10 | 1998-01-06 | Genetronics, Inc. | Electroporation and iontophoresis catheter with porous balloon |
Non-Patent Citations (1)
Title |
---|
See also references of EP0973579A4 * |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6778853B1 (en) | 1997-12-17 | 2004-08-17 | University Of South Florida | Electroporation device |
US6937890B2 (en) | 1998-12-17 | 2005-08-30 | University Of South Florida | Nonpenetrating electroporation device |
US6314316B1 (en) | 1998-12-17 | 2001-11-06 | University Of South Florida | Nonpenetrating electroporation device and method |
AU768451B2 (en) * | 1998-12-17 | 2003-12-11 | University Of South Florida | Nonpenetrating electroporation device |
WO2000035532A1 (en) | 1998-12-17 | 2000-06-22 | University Of South Florida | Nonpenetrating electroporation device |
EP1504787A1 (en) | 1998-12-17 | 2005-02-09 | University of South Florida | Nonpenetrating electroporation device |
JP2002535100A (en) * | 1999-01-28 | 2002-10-22 | サイト パルス サイエンシズ、インコーポレイテッド | Delivery of macromolecules into cells |
US8600494B2 (en) | 1999-04-09 | 2013-12-03 | Ionix Medical Inc. | Method and device for treating abnormal tissue growth with electrical therapy |
US8014854B2 (en) | 1999-04-09 | 2011-09-06 | Ionix Medical Inc. | Method and device for treating abnormal tissue growth with electrical therapy |
EP1237620B1 (en) * | 1999-12-15 | 2004-11-24 | University of South Florida | Electroporation device |
WO2001043817A1 (en) | 1999-12-15 | 2001-06-21 | University Of South Florida | Electroporation device and method |
JP2003516829A (en) * | 1999-12-15 | 2003-05-20 | ユニヴァーシティ オブ サウス フロリダ | Electroporation element and electroporation method |
US7742811B2 (en) | 2000-03-13 | 2010-06-22 | Onco Stim | Implantable device and method for the electrical treatment of cancer |
US8024048B2 (en) | 2000-03-13 | 2011-09-20 | Ionix Medical Inc. | Method and device for treating cancer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy |
EP1515775A4 (en) * | 2002-05-07 | 2010-03-03 | Oncostim Inc | Method and device for treating concer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy |
EP1515775A2 (en) * | 2002-05-07 | 2005-03-23 | SCHROEPPEL, Edward A. | Method and device for treating concer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy |
FR2872055A1 (en) | 2004-06-24 | 2005-12-30 | Yves Leon Scherman | Apparatus for transferring active principle molecules into tissue cells using one or two physical forces has two electrode needles and one or more injection needles |
FR2872056A1 (en) | 2004-06-24 | 2005-12-30 | Yves Scherman | Injection apparatus for active principles, comprises using a combination of needle and plate electrodes for enhanced penetration |
FR2880808A1 (en) | 2005-01-20 | 2006-07-21 | Yves Scherman | Active material e.g. nucleotide, delivering device for providing e.g. chemotherapy, has electric current generator, electrodes connected to respective terminals of current generator and injection needle centered between electrodes |
WO2008146075A1 (en) * | 2007-05-31 | 2008-12-04 | Biophox Gmbh & Co. Kg | Device for treating tumors |
US10575899B2 (en) | 2008-08-20 | 2020-03-03 | Prostacare Pty Ltd | Non-thermal ablation system for treating BPH and other growths |
US9211155B2 (en) | 2008-08-20 | 2015-12-15 | Prostacare Pty Ltd. | Non-thermal ablation system for treating BPH and other growths |
US9597145B2 (en) | 2008-08-20 | 2017-03-21 | Prostacare Pty Ltd | Non-thermal ablation system for treating tissue |
US10085800B2 (en) | 2008-08-20 | 2018-10-02 | Prostacare Pty Ltd | Non-thermal ablation system for treating tissue |
US10736689B2 (en) | 2008-08-20 | 2020-08-11 | Prostacare Pty Ltd | Low-corrosion electrode for treating tissue |
US10842555B2 (en) | 2008-08-20 | 2020-11-24 | Prostacare Pty Ltd | Catheter for treating tissue with non-thermal ablation |
US10939957B2 (en) | 2008-08-20 | 2021-03-09 | Prostacare Pty Ltd | Non-thermal ablation system for treating tissue |
EP2470255A4 (en) * | 2009-08-24 | 2013-02-06 | Ron L Alterman | Apparatus for trans-cerebral electrophoresis and methods of use thereof |
EP2470255A1 (en) * | 2009-08-24 | 2012-07-04 | Ron L. Alterman | Apparatus for trans-cerebral electrophoresis and methods of use thereof |
US11457975B2 (en) | 2017-11-27 | 2022-10-04 | Prostacare Pty Ltd | Apparatus and a method for the treatment of a prostatic disease |
US11224474B2 (en) | 2018-02-28 | 2022-01-18 | Prostacare Pty Ltd | System for managing high impedance changes in a non-thermal ablation system for BPH |
Also Published As
Publication number | Publication date |
---|---|
CA2287366A1 (en) | 1998-10-29 |
AU734611B2 (en) | 2001-06-21 |
EP0973579A4 (en) | 2000-11-02 |
EP0973579A1 (en) | 2000-01-26 |
US6278895B1 (en) | 2001-08-21 |
JP2001522274A (en) | 2001-11-13 |
US5873849A (en) | 1999-02-23 |
AU7151598A (en) | 1998-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU734611B2 (en) | Electrodes and electrode arrays | |
CA2218255C (en) | Method of treatment using electroporation-mediated delivery of drugs and genes | |
RU2168337C2 (en) | Method for treating diseases by administering medicinal preparations and genes by means of electroporation | |
US6662044B2 (en) | Iontophoresis, electroporation and combination patches for local drug delivery to body tissues | |
US7781195B1 (en) | Electroporation device | |
US8235966B1 (en) | Electromanipulation method | |
JP2002535100A (en) | Delivery of macromolecules into cells | |
US6314316B1 (en) | Nonpenetrating electroporation device and method | |
CA2339371C (en) | Electrically mediated angiogenesis | |
JP2003516829A (en) | Electroporation element and electroporation method | |
AU2004201004B2 (en) | Nonpenetrating electroporation device | |
AU5081799A (en) | Electroporation electrodes | |
Heller et al. | Electroporation device | |
Hoff et al. | Electromanipulation device and method | |
MXPA97008316A (en) | Method of treatment using administration of drugs and genes through electroporac |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2287366 Country of ref document: CA Ref country code: CA Ref document number: 2287366 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/009721 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 546336 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998918621 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 71515/98 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1998918621 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 71515/98 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998918621 Country of ref document: EP |